

Injectable Drug Delivery

To book online go to: management-forum.co.uk/1754

W

Date and venue

22-23 March 2018

Ref: 10154

Le Meridien Piccadilly Hotel

21 Piccadilly
London
W1J 0BH
Tel: +44 (0)20 7734 8000

Programme schedule

Registration and refreshments - 09.00

Day one 09.30 - 17.30

Drinks reception 17.30 - 18.30

Day two 09.00 - 16.15

Accommodation

The Cavendish Hotel

81 Jermyn Street
London SW1Y 6JF
Tel: +44 (0)20 7930 2111
(5 minutes walk from Le Meridien, Piccadilly)

Alternative accommodation:

The Hilton London Green Park

Half Moon Street
London W1J 7 BN
Tel: +44 (0)20 7629 7522
(15 minutes walk from Le Meridien, Piccadilly)

For information on alternative accommodation please visit our website: management-forum.co.uk/venue



Three ways to book

management-forum.co.uk info@management-forum.co.uk

+44 (0)20 7749 4730

Fees and payment

EARLY BOOKING DISCOUNT Book BEFORE 12 January 2018

£1299.00 + VAT = £1558.80 • £1819.00 + VAT = €2182.80

FULL PRICE

Book BEFORE 12 January 2018

£1499.00 + VAT = £1798.80 • £2099.00 + VAT = €2518.80

Multiple booking discount for 2nd or subsequent delegates - 15%

£1274.15 + VAT = £1528.98 • £1784.15 + VAT = €2140.98

Payment options

1. Invoice which can be paid by bank transfer or credit / debit card
2. Online through our secure website when registering

Exhibition opportunities available. Please contact Customer Services on +44 (0)20 7749 4730 or email: info@management-forum.co.uk

Please note we are also running our annual Pre-Filled Syringes seminar on the 21 March 2018 and should you wish to attend both the Pre-Filled Syringes and the Injectable Drug Delivery events, there is a further discount of £200/€280 discount

The small print

FEE: The fee includes all meals and refreshments for the duration of the course and a complete set of course materials. If you have any particular requirements please advise customer services when booking.

HOW TO REGISTER AND PAY: A VAT invoice and booking confirmation will be sent within 7 days, please contact us if you have not heard anything after that time. Payment can be made by credit/debit card, by bank transfer (for bank account details please see payment details section on our website). VAT no GB 341232109. Any questions please contact Customer Services on +44 (0)20 7749 4730. **ALL PAYMENTS MUST BE RECEIVED IN ADVANCE OF THE EVENT.**

MULTIPLE BOOKING DISCOUNTS: This discount may not be used in conjunction with any other offer

CANCELLATIONS AND TRANSFER: Once we have received your booking the place(s) are confirmed.

Delegate	Up to 28 days before course	27 to 14 days before course	13 to 0 days before course
Cancellation	10% admin fee	100% admin fee	100% admin fee
Transfers	Free	10% admin fee	100% admin fee
Substitution	Free	Free	Free

A maximum of one transfer is allowed. After the transfer no cancellation can be accepted and the full invoiced fee will be charged. Transfers are subject to payment of the difference on higher value courses. All cancellations must be received in written form.

[For event cancellation policy and T&Cs see website](#)

Book Before
12 January 2018
and SAVE £200/€280

Exhibitors include:

Harro Höfliger

ON drugDELIVERY

3P innovation

MANAGEMENT forum

The essential annual conference for pharmaceutical and medical device professionals in the parenteral drug delivery industry

Injectable Drug Delivery

Advances in technology for pens, auto-injectors, large volume pumps, patch pumps, needle-free, pre-filled syringes and other parenteral methods.

22-23 March 2018 London



Benefits in attending:

- **Hear** the latest trends in injectable drug delivery
- **Know** what is in development and recently launched on the market
- **Understand** the latest technologies using parenteral methods
- **Keep** abreast of market opportunities
- **Consider** opportunities with connectivity and smart pen injectors
- **Clarify** the importance of human factor studies and compliance monitoring
- **Meet** other medical device and pharmaceutical professionals in the parenteral market

Chairman:

Dr Gregory Berman, Independent Consultant

With a panel of international speakers

Exhibition opportunities available

CPD CERTIFIED
The CPD Certification Service

Introduction

The pharmaceutical industry and its main markets continue to change. Geopolitical changes influence healthcare industry funding models, demographic changes (in developed countries) increase the demand for healthcare and technology advancement opens up new opportunities. In drug delivery we have witnessed a very significant transition. For many years oral tablets held the leading market positions. For example, at one time oral H2 receptor blockers were the blockbusters. These were replaced by proton pump inhibitors and then cholesterol lowering drugs as the world's biggest sellers. Today, depending upon which list you look at, around 9 of the world's 12 best-selling drugs require a drug delivery device, as they are biologics for parental delivery or drugs for treatment of asthma, requiring an inhaler.

Injection devices to deliver the latest generation of drugs are evolving. First generation devices were typically mechanical and functioned only to get the drug into the body. Increasingly, in next generation parenteral devices, the drug delivery device is recognised as the interface between the drug and the patient. It can offer many features and functions which improve usability, safety, efficacy and compliance, plus many other functions beyond such as connectivity and diagnostics.

This conference looks at the latest trends, technologies and applications.

Three reasons to attend this event

- 1. An extremely valuable update on the advances in injection technology
- 2. An opportunity to keep abreast of business opportunities in the market
- 3. The chance to develop significant business partnerships

Chairman:

Dr Gregory Berman, Independent Consultant, UK

Expert faculty:

Markus Bauss, Managing Director, SHL Group, Germany
Mark Chipperfield, Company Director and Principal Consultant, Corvus Device, UK
Arnaud Guillet, Business Development Associate, Bicorp, France
Ian Thompson, Vice President Business Development, Ypsomed, Switzerland
Ian Wands, Market Development Specialist, DuPont Performance Materials, UK
Jonathan Bradshaw, Device Development Engineer, Oval Medical Technologies, UK
Stephen Dew, Associate Director RA (CMC) Combination Products, Biogen, UK
Greg Thay, Human Factors Director, Medical Devices, Thay Medical, UK
Neil Williams, Director, Front-End Innovation, Head of Connected Health, Medicom Innovation Partner, UK
Andrew Coats, Director of Engineering, Portal Instruments, USA
Mike Hooven, CEO, Enable Injections, USA
Joe Reynolds, Research Manager, Noble, UK
Andreas Rothmund, Qualified Person, Vetter Pharma-Fertigung GmbH & Co KG Germany
Suzette Roan, Senior Director, Global Regulatory Affairs, Sanofi, USA
Dr David Jefferys, Senior Vice President Global Regulatory, Government Relations and European Product Safety, Eisai Europe Ltd, UK

A certificate of attendance for professional development will be given to each participant who completes the conference

Day one		
09.00	▶	Registration and refreshments
09.30	▶	Chairman's welcome and introduction Dr Greg Berman, Independent Consultant, UK
09.40	▶	Trends in injection devices - Needs - the evolving patient, market, industry and regulatory expectations - Approaches: responding with appropriate solutions - Solutions: Some optimised, customised and novel technologies - Pathways: Navigating designations and the changing framework - Outcomes: Recent approvals, setbacks and regulator feedback Mark Chipperfield, Company Director and Principal Consultant, Corvus Device, UK
10.20	▶	Latest devices – connectivity with injectables Improved patient health and adherence through new technologies Markus Bauss, Managing Director, SHL Group, Germany
11.00	▶	Discussion followed by refreshments
11.30	▶	Ypsomed delivery systems for large volume self-injection and connectivity - Recent self-injection market trends with a focus on autoinjectors - SmartPilot reusable add-ons and their integration into the connected ecosystem - YpsoDose patch injector: making life simpler for patients and pharma companies Ian Thompson, Vice President Business Development, Ypsomed
12.10	▶	Connected health - getting to market with an electronic auto-injector, app and cloud services - Data - Analytics - Artificial intelligence Neil Williams, Director, Front-End Innovation, Head of Connected Health, Medicom Innovation Partner, UK
12.50	▶	Discussion followed by Lunch
14.10	▶	Pre-filled syringes over time - Evolution of processes and equipment - Evolution of components - Evolution of applications and application systems Andreas Rothmund, Qualified Person, Vetter Pharma-Fertigung GmbH & Co KG Germany
14.50	▶	Using polymeric PDC technology to improve auto-injector design - Polymeric primary drug container (PDC) technology unlocks the design freedom constraints of existing PDC systems, providing the ability to fully address both the needs of the user and drug - Increased design freedoms allow PDC components to be configured freely to resolve issues typically seen with glass-based systems - An integrated approach to device design reduces the impact on the user, whilst ensuring all required user interface features are present without compromise to overall device size or usability - Oval's subcutaneous platform, Sumalen Ovali, embodies this integrated philosophy to device design - Combining both user and drug requirements into its development, the platform provides a patient-centric device for delivery of Sumatriptan to migraine and cluster headache sufferers - The subcutaneous auto-injector platform actively decouples the drug delivery requirements from those of the user interface providing both user and drug delivery benefit Jonathan Bradshaw, Device Development Engineer, Oval Medical Technologies, UK
15.30	▶	Discussion followed by refreshments
16.00	▶	Polymers for better injection devices - Functional Integration of parts with Engineering Polymers - Designing for low and consistent frictional performance - Predicting long term performance under load Ian Wands, Market Development Specialist, DuPont Performance Materials, UK
16.40	▶	Large volume injectors: one device - multiple solutions - Viscosity and volume challenges with biologics - Increase in promising new biologics and biosimilars to treat multiple disease states - Subcutaneous injection of biologics: Overcoming the volume challenge - Wearable Large Volume Injectors (LVIs): An Elegant solution - Wider implications of wearable LVIs: A hand-in-glove fit with the new healthcare paradigm - Considerations in choosing a wearable high volume subcutaneous delivery device - Pharma-device partnerships: Early clinical collaboration Mike Hooven, CEO, Enable Injections, USA
17.20	▶	Discussion followed by close of day one
17.30-18.30		Networking drinks reception

Day two		
09.00	▶	Review of day one Dr Greg Berman, Independent Consultant, UK
09.10	▶	What do pharma companies want from devices? - Key considerations- improving the benefit risk profile, enhancing patient compliance - Contribution to successful life cycle management - Implications from Brexit and the new implementation of the new legislation - How to avoid disappointment Dr David Jefferys, Senior Vice President Global Regulatory, Government Relations and European Product Safety, Eisai Europe Ltd, UK
09.50	▶	The EU regulatory framework for injectable delivery systems - Classification – getting it right from the start - Implications of the new EU Medical Device Regulations for drug delivery - systems - Device essential requirements for Injectable Medicinal Products Stephen Dew, Associate Director RA (CMC) Combination Products, Biogen, UK
10.30	▶	Discussion followed by refreshments
11.10	▶	US regulatory considerations for injectable delivery systems - Implementing 21 CFR 4: Integrated development and product maintenance - Integrating essential performance into control strategy - Approaches for bridging changes made during development - Regulatory submission strategies for initial registration, post-approval changes, platform technologies and master files Suzette Roan, Senior Director, Global Regulatory Affairs, Sanofi, USA
11.50	▶	Advances in Needle Free Drug Delivery - Portal Instruments is developing a next generation needle-free drug injection platform to transform the drug delivery experience for patients suffering from chronic diseases such as ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis - Our approach, which is issued from MIT research, uses a computer-controlled linear actuator that pressurizes the medication and injects it in a very fine jet - It can administer up to 1 mL of medication, is relatively quiet, fast, and automatically adapts to both the viscosity and temperature of the medication - Clinical studies we've conducted have shown that patients perceive less pain and prefer the Portal Needle-free injector versus needle and syringe injections Andrew Coats, Director of Engineering, Portal Instruments, USA
12.30	▶	Discussion followed by Lunch
14.00	▶	Enhance existing devices or move to brand new integrated solutions? Two approaches for smart pen injectors - Moving towards connected devices in the field of injection seems inevitable: two approaches are possible to achieve this goal - Some benefits of connectivity: automatic collection of treatment information (dose, time and date), reminders, alerts, treatment calendar on the smartphone, advice, engagement... - The advantages of Add-On approach: seamless for the patients (do not change patient's habits, same device, same use), painless for the pharma (regulatory and industrial processes remain unchanged) - The advantages of integrated solutions: enhance accuracy, comfort, and security - Elements to consider in order to make a choice: time to market, regulatory environment, specific needs (dosage, comfort), maturity of the market Arnaud Guillet, Business Development Associate, Bicorp, France
14.40	▶	Human factors in injectable drug delivery - Current climate - Understanding anthropometrics and ergonomics to meet patient needs - Use safety in performing injections and infusions - Human Factors testing injection and infusion systems - Case Study: An injection aid Greg Thay, Human Factors Director, Medical Devices, Thay Medical, UK
15.20	▶	Key training device considerations for injection based therapies - Market needs and trends - User needs and characteristics - Training device considerations (AI, PFS, Onbody, etc.) - Best practices (Process, systems, innovation) - Case study/Research findings (TBD) Joe Reynolds, Research Manager at Noble, UK
16.00	▶	Discussion and Chairman's closing remarks
16.15	▶	Close of forum and refreshments
Please note we are also running our annual Pre-Filled Syringes seminar on the 21 March 2018 and should you wish to attend both the Pre-Filled Syringes and the Injectable Drug Delivery events, there is a further discount of £200/€280		
Exhibition opportunities available Please contact Customer Services on +44 (0)20 7749 4730 or email: info@management-forum.co.uk		

